LIM and SH3 protein 1 (LASP-1) is demonstrated to play a key role in occurrence and development of tumors. However, the expression and function of LASP-1 in cholangiocarcinoma (CCA) remain largely unexplored. This study aimed to investigate the effect of regulated LASP-1 expression on migration, invasion, proliferation, and apoptosis of CCA cells and on tumorigenesis in vivo, and to examine clinico-oncological correlates of LASP-1 expression. Expression of LASP-1 by immunohistochemistry was evaluated in CCA tissue samples. HCCC-9810 and RBE cells were transfected with the LASP-1 small interfering RNA (siRNA), and the effect of knocking down LASP-1 gene expression on cell migration, invasion, proliferation, and apoptosis were examined by wound healing, transwell assays, CCK-8 assays, colony formation, and flow cytometry assays, respectively. Xenograft tumor model was used to validate the effect of downregulated LASP-1 in vivo. Our results demonstrated that LASP-1 was over-expressed in CCA tissues, positively correlating with larger tumors, poor histological differentiation, lymph node metastasis, advanced TNM stage, and poor prognosis in CCA patients (P < 0.05). Downregulation of LASP-1 in HCCC-9810 and RBE cell lines significantly increased cell apoptosis and suppressed cell migration, invasion, and proliferation in vitro and tumorigenesis in vivo. Our results indicate that LASP-1 may essentially involve in the metastasis and growth of CCA and clinical significance of LASP-1 may reside in function as a biomarker to predict prognosis and as a promising therapeutic strategy for CCA patients by the inhibition of LASP-1 expression.
This is a preview of subscription content, log in to check access.
This study was supported by the Introductory Funding project from Shanghai Science and Technology Bureau (124119a0600) to WG and Science and Technology funding project of Shanghai Jiao Tong University, School of Medicine (13xj22003) to BFC.
Compliance with ethical standards
This study was performed with approval of the Ethics Committee of Xinhua Hospital and the ethical guidelines of the Declaration of Helsinki. In addition, written informed consent was obtained from all participants.
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (Shanghai, China).
Schweitzer N, Vogel A. Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 2015;29:345–53.CrossRefPubMedGoogle Scholar
Kongpetch S, Jusakul A, Ong CK, Lim WK, Rozen SG, Tan P, et al. Pathogenesis of cholangiocarcinoma: from genetics to signalling pathways. Best Pract Res Clin Gastroenterol. 2015;29:233–44.CrossRefPubMedGoogle Scholar
Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, et al. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics. 1995;28:367–76.CrossRefPubMedGoogle Scholar
Pappas CT, Bliss KT, Zieseniss A, Gregorio CC. The nebulin family: an actin support group. Trends Cell Biol. 2011;21:29–37.CrossRefPubMedGoogle Scholar
Frietsch JJ, Grunewald TG, Jasper S, Kammerer U, Herterich S, Kapp M, et al. Nuclear localisation of lasp-1 correlates with poor long-term survival in female breast cancer. Br J Cancer. 2010;102:1645–53.CrossRefPubMedPubMedCentralGoogle Scholar
Takeshita N, Mori M, Kano M, Hoshino I, Akutsu Y, Hanari N, et al. Mir-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating lasp1. Int J Oncol. 2012;41:1653–61.PubMedGoogle Scholar
Zheng J, Yu S, Qiao Y, Zhang H, Liang S, Wang H, et al. Lasp-1 promotes tumor proliferation and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol. 2014;140:1891–9.CrossRefPubMedGoogle Scholar
Salvi A, Bongarzone I, Ferrari L, Abeni E, Arici B, De Bortoli M, et al. Molecular characterization of lasp-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. Int J Oncol. 2015;46:1901–12.PubMedPubMedCentralGoogle Scholar
Zhao T, Ren H, Li J, Chen J, Zhang H, Xin W, et al. Lasp1 is a hif1alpha target gene critical for metastasis of pancreatic cancer. Cancer Res. 2015;75:111–9.CrossRefPubMedGoogle Scholar
Orth MF, Cazes A, Butt E, Grunewald TG. An update on the lim and sh3 domain protein 1 (lasp1): a versatile structural, signaling, and biomarker protein. Oncotarget. 2015;6:26–42.PubMedGoogle Scholar
Opferman JT. Attacking cancer’s Achilles heel: antagonism of anti-apoptotic bcl-2 family members. FEBS J. 2015.Google Scholar
Zhu AX. Future directions in the treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:355–61.CrossRefPubMedGoogle Scholar
Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, et al. Promotion of colorectal cancer growth and metastasis by the lim and sh3 domain protein 1. Gut. 2010;59:1226–35.CrossRefPubMedGoogle Scholar
Ardelt P, Grunemay N, Strehl A, Jilg C, Miernik A, Kneitz B, et al. Lasp-1, a novel urinary marker for detection of bladder cancer. Urol Oncol. 2013;31:1591–8.CrossRefPubMedGoogle Scholar
Wang H, Li W, Jin X, Cui S, Zhao L. Lim and sh3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer (Oxford, England : 1990). 2013;49:974–83.CrossRefGoogle Scholar
Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, et al. Silencing of lasp-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 2006;312:974–82.CrossRefPubMedGoogle Scholar
Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–40.CrossRefPubMedPubMedCentralGoogle Scholar
Chou YS, Yang MH. Epithelial-mesenchymal transition-related factors in solid tumor and hematological malignancy. J Chin Med Assoc. 2015;78:438–45.CrossRefPubMedGoogle Scholar
Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang F, et al. Lim and sh3 protein 1 induces tgfbeta-mediated epithelial-mesenchymal transition in human colorectal cancer by regulating s100a4 expression. Clin Cancer Res. 2014;20:5835–47.CrossRefPubMedGoogle Scholar
Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16:2129–44.CrossRefPubMedGoogle Scholar
Li B, Zhuang L, Trueb B. Zyxin interacts with the sh3 domains of the cytoskeletal proteins lim-nebulette and lasp-1. J Biol Chem. 2004;279:20401–10.CrossRefPubMedGoogle Scholar
Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, et al. Overexpression of lasp-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer. 2007;96:296–305.CrossRefPubMedPubMedCentralGoogle Scholar
Choi YH, McNally BT, Igarashi P. Zyxin regulates migration of renal epithelial cells through activation of hepatocyte nuclear factor-1beta. Am J Physiol Renal Physiol. 2013;305:F100–10.CrossRefPubMedPubMedCentralGoogle Scholar